We were recently granted our European Patent for a Peripheral Stent with Spiral Flow Technology marking the latest step in our journey to commercialize transformational medical devices using their platform Spiral Laminar Flow Technology (SLFTM).
Craig Dunlop (General Manager) stated “Following on from our USA patent, we are delighted to see a further expansion of our patent portfolio with the incorporation of Spiral Laminar Flow Technology into peripheral stents”. “The majority of treatment modalities currently available to clinicians to treat peripheral arterial disease act as vessel liners and have no direct impact on the blood flow. The Spiral Laminar Flow inducer in our stent design aims to increase long term patency, decrease neointimal hyperplasia, reduce junctional zone restenosis and, most importantly, reduce overall disease progression”.
“We intend to commercialise this technology through strategic commercial partnerships, combining our unique technology with current market leading devices will deliver the best possible patient treatments for peripheral arterial disease”. We welcome enquiries from interested parties.”